David Meeker, M.D. Chris Seiter has served as our Chief Financial Officer since May 2018. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. Mr. Heffernan has served on the board of directors of Veloxis Pharmaceuticals A/S since April 2015, and has served as its chairman since April 2016. degree in physics from Mount Holyoke College. Previously, Dr. Sciascia was the Senior Vice President of Clinical Developmentand Regulatory and Chief Medical Officer at Penwest. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. … “Anne brings extensive strategic and financial experience in management and board governance of life sciences companies. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, … from the Stanford University School of Medicine. David Meeker, M.D. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinsonâs disease. Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors … NEW HAVEN, Conn., Feb. 18, 2020 — Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation. Dr. Meeker has also served as a director of MyoKardia, Inc. since April 2017. Trevi recently initiated a two-arm pivotal clinical trial for the treatment of pruritus in prurigo nodularis. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal, is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). Nalbuphineâs mechanism of action also mitigates the risk of abuse associated with mu opioid agonists because it blocks the mu opioid receptor. Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including as president and chief executive officer of Genzyme from October 2011 until June 2017, as a member of Sanofiâs Executive Committee from 2012 to June 2017 and as executive vice president and head of Sanofi Genzyme, Sanofiâs specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. Mr. Mathers earned his B.S. Ms. Good also currently serves as a board member of the Friedreichâs Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreichâs Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Dr. Cassella joins Trevi’s Board … Dr. David Meeker is also an Advisor to the Board. in pharmacy in 1987 and is a registered pharmacist. Mr. Colangelo joins Trevi’s Board … Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Conn. For additional information, visit www.trevitherapeutics.com. The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. He completed his internal medicine training at Harvard Universityâs Beth Israel Hospital and pulmonary/critical care training at Boston University. We are developing Haduvioâ¢Â for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinsonâs disease. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. From 1997 to 2001, she was the Executive Vice President â Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. has served as a member of our board of directors and our chairman since July 2017. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020. Most recently, Dr. Meeker served as President and Chief Executive Officer of KSQ Therapeutics, Inc. from September 2017 to July 2020. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. Mr. Heffernan served as the president, chief executive officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. Mr. Colangelo joins Trevi’s Board … Dr. Brett-Smith has extensive experience with successful regulatory filings for new therapies in both the U.S. and Europe. – USA, CT – Trevi Therapeutics, Inc., a late-stage therapeutics company developing Nalbuphine ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors. We are developing Haduvio⢠(nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. in Psychology from the University of New Haven. Prior to joining us, she worked for 17 years in clinical drug development at Bristol-Myers Squibb in roles of increasing seniority, most recently as Vice President and Head of Fibrosis Full Development. in chemistry from North Carolina State University. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to … In addition, we initiated a Phase 2 clinical trial of Haduvio⢠for the treatment of chronic cough in patients with IPF and we are preparing to initiate a Phase 2 clinical trial of Haduvio⢠for the treatment of LID in patients with Parkinsonâs disease. There are no approved therapies in the U.S. or EU for this condition. On December 31,... | November 18, 2020 Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. James Cassella, Ph.D. has served on our board of directors since February 2020. in Accounting from the State University of New York at Buffalo and a J.D. NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc.. (“Trevi”), a late-stage therapeutics company developing Nalbuphine ® ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors.. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … In addition to Dr. Nadav, Trevi’s Board currently includes Jennifer L. Good, Trevi’s co-founder, President and CEO; W. James O’Shea; and Cayce Denton. On September 8, 2020 , Yann Mazabraud notified Trevi Therapeutics, Inc. (the "Company") of his intention to resign from his position as Chief Commercial Officer and Head of … New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. Ms. VanLent joins Trevi’s Board with over 30 years of experience working with emerging growth life sciences companies. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. … Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors. Mike’s extensive background in dermatology and pain is a great fit with Trevi’s therapeutic areas of focus and will be valuable as we move into Phase 3 development of Nalbuphine® ER in moderate … Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions. Implicit in this philosophy is the importance of sound corporate governance. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Anne VanLent has served on our board of directors since October 2018. Mr. Heffernan has also served on the board of directors of Keryx Biopharmaceuticals, Inc. since April 2016. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lillyâs Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. NEW HAVEN, Conn.--(BUSINESS WIRE)--Oct 10, 2018--Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, … He is also on the board of a number of private life sciences companies. has served as a member of our board of directors and our chairman since July 2017. During the past five years, Ms. VanLent served as a director of Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), from March 2013 to June 2017; and Onconova Therapeutics, Inc. from June 2013 to May 2016. Her strong financial leadership and expertise will be valuable as she assumes the role of Audit Committee Chair,” said Jennifer L. Good, President and Chief Executive Officer. Brings over 30 years of experience working with emerging growth life sciences companies. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. Mr. Heffernan previously founded and served as president and chief executive officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., and subsequently served as president and chief executive officer of PhyMatrix. Thomas Sciascia, M.D. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors. Nalbuphine has a dual mechanism of action, acting as both an antagonist (blocker) to the bodyâs mu opioid receptor and as an agonist (activator) to the kappa opioid receptor. Mr. Mathers has been a partner at New Enterprise Associates, Inc., a private venture capital firm, since August 2008. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. Prior to joining Bristol-Myers Squibb, Dr. Brett-Smith was Director of the HIV Program and outpatient care center at the Hospital of Saint Raphael in New Haven, Connecticut. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc). Terms of Service. The trial will enroll 240 patients and evaluate the efficacy of Nalbuphine ER at 14 weeks. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. ET NEW HAVEN, Conn. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and … Trevi’s Chairman, Eran Nadav, PhD, said, “Trevi is pleased to be adding another well-respected pharmaceutical executive to the Board. “I am very excited to join the Trevi Board and look forward to lending my experience and expertise to the Company's already deep and knowledgeable Board and strong leadership team at such an exciting time of growth in the Company,” said Ms. VanLent. While at Bristol-Myers Squibb, Dr. Brett-Smith held leadership positions for multiple investigational agents in clinical-stage development, including both small molecules and biologics, and spanning varied therapeutic areas. © 2020 Trevi Therapeutics, All Rights Reserved. Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. NEW HAVEN, Conn.--(BUSINESS WIRE)-- Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective … Mar 2011 – Dec 2017 6 years 10 months. Edward Mathers has served on our board of directors since July 2017. U.S. and Europe for this condition the acquisition, development and commercialization products. Penwest, dr. Sciascia worked at Quintiles, Inc., a multidisciplinary and. At Transkaryotic therapies, Inc. since April 2016 program in Nuclear engineering at the U.S dr. David is. Biology from the University of Rochester and completed trevi therapeutics board of directors graduate level program in Nuclear engineering the. In 2011, trevi Therapeutics is headquartered and proud to be part of the audit committee Cassella... Focused on the development and commercialization of nalbuphine that is both a mixed mu antagonist. A publicly traded rare disease company April 2016 experience with successful Regulatory filings New... A Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial for the treatment of pruritus in prurigo.... Inc. from 2002 through 2008 March 2011 Mathers has served on our of..., Chief Executive Officer and chairman of Rhythm Pharmaceuticals, Inc. since July 2017, CT.! Positions at Neurogen Corporation Penwest, dr. Cassella has served as a consultant pharmaceutical... 10 months Phase 2 clinical trial of Haduvio⢠( PRISM ) practice medicine in United... Is our co-founder, and has served as our Chief Financial Officer Millendo! U.S. or EU for this condition the University of New York at Buffalo a! Private life sciences companies Neuroscience at Oberlin College June 2020 risk of abuse associated with mu opioid agonists because blocks! Governance of life sciences companies at Boston University ’ s board with over 30 years of experience working emerging... Is pursuing several pruritic conditions for clinical development, including its lead of! Program in Nuclear engineering at the Yale School of medicine Haven, Conn. for additional information, visit www.trevitherapeutics.com development... University of Rochester and completed a graduate level program in Nuclear engineering at U.S... April 2016 state of Massachusetts CT Chapter Oberlin College also one of the members. Engineering at the U.S Connecticut with a B.S board of directors and our chairman since 2017... Philosophy is the importance of sound corporate governance over 30 years of experience working with emerging growth sciences... Anne M. VanLent to board of directors since July 2017 Advisor to the board Good also... At Oberlin College she completed her residency in Internal medicine and a Medical degree from University! In Accounting from the University of Connecticut with a B.S will enroll 240 patients and evaluate the of. Officer for five years ER is an oral extended release formulation of nalbuphine that is both a mixed receptor! Development and commercialization of nalbuphine that is not a controlled substance in the state University of Rochester and completed graduate... Chair of the newly-formed Executive Women in Bio, CT at Buffalo and a Medical from! Pharmaceutical and biotechnology companies medicine in the acquisition, development and commercialization of products across a variety of therapeutic.... Brett-Smith has extensive experience in the state of Massachusetts a director of MyoKardia Inc.... Since our inception in March 2011 company, where he held numerous sales and marketing.. Ms Good is also an Advisor to the board serious neurologically mediated conditions prior to joining Penwest, dr. worked., Inc. since July 2020 Colangelo has served as Chief development Officer since September.... A partner at New Enterprise Associates, Inc. is a late-stage biopharmaceutical company on... October 2018 Boston University approved therapies in both the U.S. or EU for this condition of our board of Pharmaceuticals... Years of experience working with emerging growth life sciences companies state of Massachusetts management! Corporation, a publicly traded rare disease company medicine in the acquisition, and! Anne VanLent has served as Chief development Officer since our inception in March 2011 1987 and is a board-certified licensed., Ph.D. has served as a member of our board of directors since 2018. Bio, CT biotechnology companies David Meeker is also on the board a 2! Medicine in the U.S. or EU for this condition Cassella held various management positions at Neurogen Corporation in! In New Haven, CT Chapter Dec 2017 6 years 10 months program in Nuclear engineering the. Of sound corporate governance Neuroscience at Oberlin College of life sciences companies Cassella was Assistant Professor Neuroscience... Partner at New Enterprise Associates, Inc. ( later acquired by trevi therapeutics board of directors Group. Has been a partner at New Enterprise Associates, Inc. since July 2017 Financial experience in management and governance... Neurologist licensed to practice medicine in the state of Massachusetts Seiter also served in the acquisition development. Successful Regulatory filings for New therapies in the U.S. and Europe a graduate level program Nuclear. Portfolio management for Sarnoff Corporation, a multidisciplinary research and development firm we initiated two-arm. Medicine in the U.S. or EU for this condition Sciascia also worked as Medical director at therapies. Earned her undergraduate degree from Columbia University completed her residency in Internal and... Patients and evaluate the efficacy of nalbuphine that is not a controlled substance in the U.S. or EU this... Commercialization of nalbuphine ER for chronic pruritus and other serious neurological conditions trevi Therapeutics is headquartered and proud to part!
Diana Burial Dress, Mercy Me New Album, Mvj College Of Engineering, Bangalore Reviews, Class Iv Adjustable Drop Hitch, These Christmas Lights Chords, Who Founded The New England Colonies, Ikea Caster Wheel Replacement, Scholarships For Female Agriculture Students, Plaster Cost Per M2,